Citius Pharmaceuticals to Feature Product Candidates Including Stem-Cell Therapy for COVID-19-Related Acute Respiratory Conditions at H.C. Wainwright Global Life Sciences Conference March 9-10
Citius Pharmaceuticals (Nasdaq: CTXR) will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. CEO Myron Holubiak will provide updates on the company's product pipeline, including Mino-Lok, which is in Phase 3 trials. The presentation will be accessible via webcast starting March 9 at 7:00 a.m. ET, with a replay available for 90 days. The company recently issued its February 2021 Letter to Shareholders, detailing business and clinical developments. For more information, visit the company's website.
- Citius is advancing its lead product candidate, Mino-Lok, which is currently in Phase 3 trials.
- The company has increased visibility through participation in a notable conference.
- The management is engaging with investors via virtual meetings.
- None.
CRANFORD, N.J., March 4, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company developing and commercializing critical care drug products, today announced that it will present at the H.C. Wainwright Global Life Sciences Conference, to be held virtually on March 9-10, 2021. Myron Holubiak, Chief Executive Officer of Citius, will present an overview and provide an update on the Company's products under development, including its lead product candidate Mino-Lok, currently in Phase 3 trials.
The webcast of this presentation will be available to view starting on Tuesday, March 9, at 7:00 a.m. Eastern Time. Mr. Holubiak will also conduct virtual one-on-one meetings with investors during the conference.
Webcast: https://journey.ct.events/view/262c140c-bae9-4791-bee8-7a03b2d8449a
A replay of the presentation will also be available on the Company's website at https://www.citiuspharma.com/ for 90 days following the conference.
The Company recently issued its February 2021 Letter to Shareholders, highlighting recent updates on its business and clinical developments as well as news for its pipeline of products. To view the letter in its entirety, please visit: https://www.citiuspharma.com/wp-content/uploads/2021/02/CTXR_Shareholder_Letter_Feb2021.pdf
About Citius Pharmaceuticals, Inc.
Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. For more information, please visit www.citiuspharma.com.
Safe Harbor
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: market and other conditions; our ability to successfully undertake and complete clinical trials and the results from those trials for our product candidates; our need for substantial additional funds; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the early stage of products under development; the estimated markets for our product candidates and the acceptance thereof by any market; risks related to our growth strategy; patent and intellectual property matters, our ability to attract, integrate, and retain key personnel; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; our dependence on third-party suppliers; government regulation; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Contact:
Andrew Scott
Vice President, Special Projects
(O) 908-967-6677 x105
(M) 646-522-8410
ascott@citiuspharma.com
View original content:SOURCE Citius Pharmaceuticals, Inc.
FAQ
When will Citius Pharmaceuticals present at the H.C. Wainwright Conference?
What is the focus of Citius Pharmaceuticals' presentation at the conference?
How can investors view the Citius Pharmaceuticals presentation?
What recent update did Citius Pharmaceuticals provide in its February 2021 Letter to Shareholders?
What is the significance of Mino-Lok for Citius Pharmaceuticals?
